Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

NCT03311126 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

21

Enrollment

OTHER

Sponsor class

Stopped slow accrual

Conditions

Mantle Cell Lymphoma
Non-hodgkin Lymphoma
Non Hodgkin Lymphoma

Interventions

DRUG: Bendamustine
DRUG: Obinutuzumab

Sponsor

University of Wisconsin, Madison

Collaborators

[object Object]